Short-Term Metformin Treatment Enriches Bacteroides dorei in an Obese Liver Steatosis Zucker Rat Model
Obesity is the leading cause of health-related diseases in the United States and World. Previously, we reported that obesity can change gut microbiota using the Zucker rat model. Metformin is an oral anti-hyperglycemic agent approved by the FDA to treat type 2 diabetes (T2D) in adults and children o...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-03-01
|
| Series: | Frontiers in Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmicb.2022.834776/full |
| _version_ | 1828230632195489792 |
|---|---|
| author | Michael S. Robeson Kanishka Manna Christopher Randolph Stephanie Byrum Reza Hakkak Reza Hakkak Reza Hakkak |
| author_facet | Michael S. Robeson Kanishka Manna Christopher Randolph Stephanie Byrum Reza Hakkak Reza Hakkak Reza Hakkak |
| author_sort | Michael S. Robeson |
| collection | DOAJ |
| description | Obesity is the leading cause of health-related diseases in the United States and World. Previously, we reported that obesity can change gut microbiota using the Zucker rat model. Metformin is an oral anti-hyperglycemic agent approved by the FDA to treat type 2 diabetes (T2D) in adults and children older than 10 years of age. The correlation of short-term metformin treatment and specific alterations to the gut microbiota in obese models is less known. Short-term metformin has been shown to reduce liver steatosis. Here we investigate the effects of short-term metformin treatment on population of gut microbiota profile in an obese rat model. Five week old obese (n = 12) female Zucker rats after 1 week of acclimation, received AIN-93 G diet for 8 weeks and then rats were randomly assigned into two groups (6 rats/group): (1) obese without metformin (ObC), or (2) obese with metformin (ObMet). Metformin was mixed with AIN-93G diet at 1,000 mg/kg of diet. Rats were weighed twice per week. All rats were sacrificed at the end of metformin treatment at 10 weeks and fecal samples were collected and kept at −80°C. Total microbial DNA was collected directly from the fecal samples used for shotgun-metagenomics sequencing and subsequently analyzed using MetaPlAn and HUMAnN. After stringent data filtering and quality control we found significant differences (p = 0.0007) in beta diversity (Aitchison distances) between the ObC vs. ObMet groups. Supervised and unsupervised analysis of the log-ratios Bacteroides dorei and B. massiliensis vs. all other Bacteroides spp., revealed that B. dorei and B. massiliensis were enriched in the ObMet group, while the remaining Bacteroides spp. where enriched in the ObC group (p = 0.002). The contributional diversity of pathways is also significantly associated by treatment group (p = 0.008). In summary, in the obese Zucker rat model, short-term metformin treatment changes the gut microbiota profile, particularly altering the composition Bacteroides spp. between ObC and ObMet. |
| first_indexed | 2024-04-12T18:51:20Z |
| format | Article |
| id | doaj.art-a9f0ea95b12d4988b2387f0f5694c7aa |
| institution | Directory Open Access Journal |
| issn | 1664-302X |
| language | English |
| last_indexed | 2024-04-12T18:51:20Z |
| publishDate | 2022-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Microbiology |
| spelling | doaj.art-a9f0ea95b12d4988b2387f0f5694c7aa2022-12-22T03:20:28ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2022-03-011310.3389/fmicb.2022.834776834776Short-Term Metformin Treatment Enriches Bacteroides dorei in an Obese Liver Steatosis Zucker Rat ModelMichael S. Robeson0Kanishka Manna1Christopher Randolph2Stephanie Byrum3Reza Hakkak4Reza Hakkak5Reza Hakkak6Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, United StatesDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR, United StatesArkansas Children’s Research Institute, Little Rock, AR, United StatesDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR, United StatesArkansas Children’s Research Institute, Little Rock, AR, United StatesDepartment of Dietetics and Nutrition, University of Arkansas for Medical Sciences, Little Rock, AR, United StatesDepartment of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, United StatesObesity is the leading cause of health-related diseases in the United States and World. Previously, we reported that obesity can change gut microbiota using the Zucker rat model. Metformin is an oral anti-hyperglycemic agent approved by the FDA to treat type 2 diabetes (T2D) in adults and children older than 10 years of age. The correlation of short-term metformin treatment and specific alterations to the gut microbiota in obese models is less known. Short-term metformin has been shown to reduce liver steatosis. Here we investigate the effects of short-term metformin treatment on population of gut microbiota profile in an obese rat model. Five week old obese (n = 12) female Zucker rats after 1 week of acclimation, received AIN-93 G diet for 8 weeks and then rats were randomly assigned into two groups (6 rats/group): (1) obese without metformin (ObC), or (2) obese with metformin (ObMet). Metformin was mixed with AIN-93G diet at 1,000 mg/kg of diet. Rats were weighed twice per week. All rats were sacrificed at the end of metformin treatment at 10 weeks and fecal samples were collected and kept at −80°C. Total microbial DNA was collected directly from the fecal samples used for shotgun-metagenomics sequencing and subsequently analyzed using MetaPlAn and HUMAnN. After stringent data filtering and quality control we found significant differences (p = 0.0007) in beta diversity (Aitchison distances) between the ObC vs. ObMet groups. Supervised and unsupervised analysis of the log-ratios Bacteroides dorei and B. massiliensis vs. all other Bacteroides spp., revealed that B. dorei and B. massiliensis were enriched in the ObMet group, while the remaining Bacteroides spp. where enriched in the ObC group (p = 0.002). The contributional diversity of pathways is also significantly associated by treatment group (p = 0.008). In summary, in the obese Zucker rat model, short-term metformin treatment changes the gut microbiota profile, particularly altering the composition Bacteroides spp. between ObC and ObMet.https://www.frontiersin.org/articles/10.3389/fmicb.2022.834776/fullobesitymetforminBacteroides doreiZucker ratgut microbiota |
| spellingShingle | Michael S. Robeson Kanishka Manna Christopher Randolph Stephanie Byrum Reza Hakkak Reza Hakkak Reza Hakkak Short-Term Metformin Treatment Enriches Bacteroides dorei in an Obese Liver Steatosis Zucker Rat Model Frontiers in Microbiology obesity metformin Bacteroides dorei Zucker rat gut microbiota |
| title | Short-Term Metformin Treatment Enriches Bacteroides dorei in an Obese Liver Steatosis Zucker Rat Model |
| title_full | Short-Term Metformin Treatment Enriches Bacteroides dorei in an Obese Liver Steatosis Zucker Rat Model |
| title_fullStr | Short-Term Metformin Treatment Enriches Bacteroides dorei in an Obese Liver Steatosis Zucker Rat Model |
| title_full_unstemmed | Short-Term Metformin Treatment Enriches Bacteroides dorei in an Obese Liver Steatosis Zucker Rat Model |
| title_short | Short-Term Metformin Treatment Enriches Bacteroides dorei in an Obese Liver Steatosis Zucker Rat Model |
| title_sort | short term metformin treatment enriches bacteroides dorei in an obese liver steatosis zucker rat model |
| topic | obesity metformin Bacteroides dorei Zucker rat gut microbiota |
| url | https://www.frontiersin.org/articles/10.3389/fmicb.2022.834776/full |
| work_keys_str_mv | AT michaelsrobeson shorttermmetformintreatmentenrichesbacteroidesdoreiinanobeseliversteatosiszuckerratmodel AT kanishkamanna shorttermmetformintreatmentenrichesbacteroidesdoreiinanobeseliversteatosiszuckerratmodel AT christopherrandolph shorttermmetformintreatmentenrichesbacteroidesdoreiinanobeseliversteatosiszuckerratmodel AT stephaniebyrum shorttermmetformintreatmentenrichesbacteroidesdoreiinanobeseliversteatosiszuckerratmodel AT rezahakkak shorttermmetformintreatmentenrichesbacteroidesdoreiinanobeseliversteatosiszuckerratmodel AT rezahakkak shorttermmetformintreatmentenrichesbacteroidesdoreiinanobeseliversteatosiszuckerratmodel AT rezahakkak shorttermmetformintreatmentenrichesbacteroidesdoreiinanobeseliversteatosiszuckerratmodel |